COVID-19 was declared a global pandemic by the WHO on March 11, 2020. Based on prior research, Melaleuca alternifolia Concentrate (MAC) oil has been found to possess antimicrobial, antiviral, anti-inflammatory, and immune-boosting properties. AVIMAC is an herbal product containing the active ingredient MAC oil, which is an isolate and extract from the Melaleuca alternifolia plant, subsequently purified through specialized technology developed by Prof. Max Reynolds, Ph.D. Clinical trials are still necessary to provide scientific evidence of AVIMAC’s use as an adjunct therapy for COVID-19.

A randomized, prospective, open-label, controlled study involving 130 subjects with mild or moderate COVID-19 who met the inclusion and exclusion criteria. Subjects were divided into 2 treatment groups, namely the group receiving standard treatment and the group receiving standard treatment plus AVIMAC. Subjects were evaluated daily during hospitalization and follow-up assessments were conducted on days 7, 9, 14, and 28.

Study was conducted from 3rd Oct, 2020 as the first date of the first subject enrolled until 25th Jan, 2021 as the last visit date of the last subject enrolled. This research was conducted at Persahabatan Hospital and Wisma Atlet emergency hospital. The research was carried out after obtaining approval from the Ethics Committee of Persahabatan Hospital and the Ethics Committee of Medical Faculty of University of Indonesia and was sponsored by PT. Neumedik Indonesia